

Gemini Stock Analysis Report

Based on the detailed analysis report provided (generated 2026-01-10), here is the positional trading assessment for **AUROPHARMA.NS**.

Step 1: Audit the Data

- **Data Present:**
 - **Price Structure:** Daily (3-Year) and Weekly candlestick charts.
 - **Trend Indicators:** Moving Averages (EMA 20, 50, 200), Supertrend, and MACD.
 - **Momentum/Volatility:** RSI, Bollinger Bands (including Band Width/Squeeze analysis).
 - **Relative Strength:** RS Ratios against the sector (CNXPHARMA).
 - **Volume:** Volume moving averages and divergence analysis.
 - **Fundamentals:** Long-term (4 years) and short-term (6 quarters) metrics, plus Analyst Estimates.
 - **Data Missing:**
 - **Detailed Order Flow:** While volume bars are present, specific delivery percentages or buyer/seller depth are not explicit (standard for this type of report).
 - **Broader Market Context:** No chart for the NIFTY50 index to gauge overall market sentiment, though Sector comparison is provided.
 - **Confidence Level: High.** The report provides a comprehensive technical and fundamental picture, including multi-timeframe analysis and specific signal dates.
-

Step 2: Analyze the Setup

- **Trend & Structure:**
 - **Long-Term: Bullish.** The stock is trading above the 200 EMA (1160.97), and a "Golden Cross" (50 EMA crossing above 200 EMA) occurred recently in late 2025.
 - **Intermediate/Short-Term:** Consolidation/Neutral. The price (1198.70) is currently trapped between the 50 EMA (support at 1188) and the 20 EMA (resistance at 1205).
 - **Volatility Squeeze (Critical):**
 - Page 14 & 15 identify a significant **Volatility Squeeze**. The Bollinger Band Width is 0.0544 (historically low). This indicates a massive energy buildup is occurring. A breakout or breakdown is imminent.
 - **Momentum & Signals:**
 - **Bearish Signs:** MACD has issued a "**Bearish** Crossover (Sell)" signal, and momentum is weakening. The price is in the "Lower Half" of the Bollinger Bands. RSI is neutral (48) but shows historic bearish divergences.
 - **Bullish Signs:** Relative Strength (RS) over 1 month and 3 months classifies the stock as an "Emerging Leader." The Supertrend is still in a Buy status (support at 1169).
 - **Confluence:**
 - The setup is a "**Squeeze Play**" at **Major Support**. The stock is compressing right above the 200 EMA and Supertrend support. While the long-term trend supports a move up, the short-term momentum (MACD) is currently dragging it down.
-

Step 3: Formulate the Recommendation

Recommendation: NO / CONDITIONAL BUY

Reasoning: While the long-term structure is bullish, entering **now** (1198.70) is premature. The MACD is bearish, and the price is trading below the 20-day EMA. The "Squeeze" indicated in the report could resolve

Gemini Stock Analysis Report

downward. You should not buy until the market proves the short-term momentum has shifted back in favor of the long-term trend.

Conditional Plan (Wait for the Breakout):

- **Condition to Buy:** The stock must signal a resolution of the squeeze to the upside. Look for a **Daily Close above 1215**.
 - *Why?* This clears the 20 EMA (1205), the Bollinger Middle Band (1205), and the recent resistance cluster.
- **Entry Price: INR 1215 - INR 1220** (Entry on confirmation).
- **Stop Loss: INR 1155** (Closing Basis).
 - *Why?* This is below the critical confluence of the 200 EMA (1160) and the Supertrend support (1169). If it loses this level, the trend has reversed.
- **Take Profit: INR 1350**
 - *Why?* This targets the recent swing highs and aligns with the upper range of the analyst estimates (Target 1301 - 1640). This offers a roughly 1:2.5 Risk/Reward ratio.

News & Analyst Targets

As a stock research analyst, I have compiled the latest research, news, and valuation data for **Aurobindo Pharma (AUROPHARMA)** for the week ending January 10, 2026.

1) Latest News for AUROPHARMA (Week of Jan 5 - Jan 10, 2026)

- **Health Canada Approval (Jan 9, 2026):**
 - **CuraTeQ Biologics**, a wholly-owned subsidiary, received a **Notice of Compliance (NOC)** from Health Canada for its biosimilar **Dyrupeg** (pegfilgrastim).
 - This drug is used to stimulate the production of white blood cells (neutrophils) in cancer patients undergoing chemotherapy. The approval validates the product's safety and quality, opening a new revenue stream in the regulated Canadian market.
 - **Acquisition Effective (Jan 1, 2026):**
 - The company's acquisition of the **branded non-oncology prescription business** of **Khandelwal Laboratories** became effective on January 1.
 - This deal, valued at **INR 325 crore**, strengthens Aurobindo's domestic portfolio in the **anti-infective and pain management** segments.
 - **Volume Spike (Jan 6, 2026):**
 - The stock witnessed a significant surge in trading volume on Tuesday, January 6, recording its highest single-day volume in nearly two months. This technical breakout was accompanied by a price gain of ~1.6%, signaling renewed investor interest.
 - **Upcoming Investor Event (Jan 13, 2026):**
 - The company has scheduled a plant visit for an investor group on **January 13, 2026**, which may lead to further analyst notes or updates next week.
-

2) Brokerage Upgrades & Downgrades

The analyst community is currently **divided** on the stock. While most retain a constructive "Buy" view based on valuation and US pipeline growth, domestic institutional investors have expressed caution regarding

Gemini Stock Analysis Report

regulatory risks.

- **Positive View (Upgrade/Maintain):**

- **Motilal Oswal** and **PhillipCapital** remain bullish, citing the company's strong US generic pipeline and the ramp-up of its Pen-G (Penicillin-G) plant, which is expected to boost margins in FY26-27.
- **Nuvama** has maintained a "Buy" rating, seeing the recent correction as an opportunity, though they slightly trimmed their target in late 2025.

- **Cautious View (Downgrade/Reduce):**

- **Kotak Institutional Equities** has maintained a "**Reduce**" (**Sell**) rating. They remain skeptical about the valuation multiples and potential pricing pressures in the US generics market.

3) Other News Impacting AUROPHARMA

- **USFDA Observations (Direct Impact):**

- In mid-December 2025, the **USFDA** issued **Form 483s** with observations for two key units:
 - **Unit-IV (APL Healthcare):** Received **5 observations** (Dec 18, 2025).
 - **Unit-V (Apitoria Pharma):** Received **3 observations** (Dec 14, 2025).
- **Analyst Take:** While the company termed these "procedural," any delay in clearing these observations could impact future approvals from these facilities.

- **Sector Trend - Biosimilars & GLP-1 (Indirect Impact):**

- The broader "Nifty Pharma" index is benefiting from the global hype around **GLP-1 (weight loss) drugs**. Aurobindo is actively developing a generic version of semaglutide (active in Ozempic/Wegovy), which is a key long-term catalyst monitored by investors.

4) Latest Analyst Targets (2026 Outlook)

Below is a summary of the most recent price targets issued by major brokerages in late 2025 and early 2026.

Brokerage Firm	Rating	Target Price (INR)	Sentiment	Date of Report
PhillipCapital	BUY	1,450	Bullish	Dec 24, 2025
Nuvama	BUY	1,420	Bullish	Nov 25, 2025
Motilal Oswal	BUY	1,430	Bullish	Dec 03, 2025
CLSA	OUTPERFORM	1,340	Moderate	Nov 06, 2025
HSBC	BUY	1,300	Moderate	Oct 13, 2025
Axis Capital	BUY	1,260	Cautious Buy	Nov 06, 2025
Kotak Equities	REDUCE	1,115	Bearish	Jan 06, 2026

- **Consensus Average Target:** ~INR 1,330
- **Current Market Price (approx):** ~INR 1,195 - INR 1,210
- **Implied Upside:** ~10-12% from current levels based on consensus.

Stock Detailed Analysis Report

AUROPHARMA.NS

Current Price: ₹1198.70

Generated: 2026-01-10 10:20

AUROPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	9.31%	10.33%
Net Income	Yes	Yes	9.86%	9.59%
ROE	No	Yes	0.41%	-0.31%
EPS	Yes	Yes	10.43%	9.79%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-7.03%	1.23%
Net Income	No	-8.71%	-2.37%
ROE	Yes	4.52%	4.52%
EPS	No	4.00%	-3.39%

AUROPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Emerging Leader
RS Score:	50.5/100
:	

== RS RATIOS ==:

1M RS:	1.012 [Leader]
3M RS:	1.011 [Leader]
6M RS:	1.037 [Leader]
1Y RS:	0.960 [Neutral]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	!! DETECTED !!
:	

SIGNAL CRITERIA::


✓ Emerging RS:	1M (1.012) > 3M (1.011)
✓ Medium-term Lagging:	1Y=0.960 (≤ 1.0)
✓ Performance Improving:	3M (+7.0%) > 6M (+5.3%)

Relative Strength Analysis: AUROPHARMA.NS vs ^CNXPHARMA
Classification: Emerging Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



AUROPHARMA.NS - EMA Crossover Summary

EMA 20:	1205.69
EMA 50:	1188.46
EMA 200:	1160.97
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-25 00:00:00+05:30
Golden Cross Price:	1208.00


AUROPHARMA.NS EMA Crossover Analysis



AUROPHARMA.NS - Bollinger Bands Summary

Current Price:	1198.70
Upper Band:	1237.96
Middle Band (SMA 20):	1205.19
Lower Band:	1172.41
%B:	0.4011
Band Width:	0.0544
Status:	Lower Half
Signal:	None


AUROPHARMA.NS Bollinger Bands (20, 2) Analysis



AUROPHARMA.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	1169.55
Signal Identified On:	2025-09-11

Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




AUROPHARMA.NS - MACD Summary

MACD Line:	5.28
Signal Line:	5.63
Histogram:	-0.34
Trend:	Bearish
Momentum:	Weakening
Signal:	Bearish Crossover (Sell)

AUROPHARMA.NS Price






AUROPHARMA.NS MACD (12, 26, 9)



AUROPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.0544
ATR:	25.2857
Total Signals:	41
Signal 1:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze at 2026-01-06 00:00:00+05:30 (Price: 1231.30)
Signal 3:	BB Squeeze at 2026-01-07 00:00:00+05:30 (Price: 1235.40)
Signal 4:	BB Squeeze at 2026-01-08 00:00:00+05:30 (Price: 1206.10)
Signal 5:	BB Squeeze at 2026-01-09 00:00:00+05:30 (Price: 1198.70)

AUROPHARMA.NS - Volatility Squeeze Analysis



AUROPHARMA.NS - RSI-Volume Summary

Current RSI:	48.77
Current Volume:	889120
Volume MA 20:	852763
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-02-03 00:00:00+05:30, Price: 1121.19
Bearish Div 1:	Date: 2024-08-30 00:00:00+05:30, Price: 1563.53
Bearish Div 2:	Date: 2025-10-13 00:00:00+05:30, Price: 1136.80

AUROPHARMA.NS RSI-Volume Divergence Analysis




Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	1122.17	1198.7	2025-11-10
1 Day	UPTREND (Buy)	1169.55	1198.7	2025-09-11
15 Min	UPTREND (Buy)	1186.59	1198.7	2026-01-09

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bearish	Weakening	Bearish Crossover (Sell)
15 Min	Bullish	Strengthening	No Signal

AUROPHARMA.NS - 1 Week (Candlestick + EMAs)




AUROPHARMA.NS - 1 Day (Candlestick + EMAs)



AUROPHARMA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - AUROPHARMA_main



Trendlyne Snapshot - AUROPHARMA_forecaster

MarketsSTARFOLIOAlertsF&OMFReportsScreenersSubscribeSuperstarsPortfolioWatchlistInsider TradesResultsData DownloaderMore

Search Stock, IPO, MF

IN

A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / AUROBINDO PHARMA LTD.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

In 2 Starfolio Baskets

1198.70

-7.40 (-0.61%)

906.8K

NSE+BSE Volume

NSE 09 Jan, 2026 3:31 PM (IST)

Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Overview

FORECASTER

STOCK REPORT

Buy Sell Zone

F&O

Financials

News

Reports

Technicals

Shareholding

Deals

Corporate Actions

Alerts

About

Aurobindo Pharma - AUROPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 28 analysts

Aurobindo Pharma has a share price target of Rs 1301, revenue growth forecast of 4.8%, and profit growth estimate of 4.8% for FY26, based on top 28 analyst calls.

Aurobindo Pharma FORECASTER - Analyst Estimates

[FORECASTER DASHBOARD](#)

SHARE PRICE TARGET FORECAST12 MONTH ESTIMATE

LOW ESTIMATE: 730, HIGH ESTIMATE: 1640, CURRENT PRICE: 1198.7, AVG. ESTIMATE: 1300.6

HIT Aurobindo Pharma's share price target is above the current price, with an upside of 8.5%

EPS FORECASTQUARTERANNUAL

Mar '23, Mar '24, Mar '25, Mar '26, Mar '27

MISS Aurobindo Pharma's EPS was lower than average estimate 2 times in past 3 years

CONSENSUS RECOMMENDATION28 ANALYST Recommendations

18	5	1	4	Aug '25
18	5	2	3	Sep '25
18	5	2	3	Oct '25
18	5	2	3	Nov '25
18	5	2	3	Dec '25
17	6	2	3	Jan '26

BUY

The consensus recommendation from 28 analysts for Aurobindo Pharma is BUY